A Multi-Site Break Through Cancer Trial: Phase II Study Investigating Dual Inhibition of BCL2 and Menin in AML MRD Using the Combination of Venetoclax and Revumenib

NCT06284486 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

8

Enrollment

OTHER

Sponsor class

Conditions

Acute Myeloid Leukemia

Interventions

DRUG: Venetoclax
DRUG: Revumenib

Sponsor

M.D. Anderson Cancer Center

Collaborators

[object Object]
[object Object]